Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
citral-enriched fraction F2
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Citral-enriched fraction F2 is a research-stage natural product fraction derived from the essential oil of *Lippia alba* (citral chemotype). It is obtained through rational fractionation techniques guided by chemical composition and cytotoxic analysis, with the monoterpene aldehyde citral as its primary active constituent. F2 is being investigated as a co-adjuvant to standard chemotherapy agents, specifically cytarabine and clofarabine, for the treatment of acute myelogenous leukemia (AML). Preclinical studies indicate that F2 exhibits synergistic pharmacological interactions with these chemotherapies, intensifying their selective cytotoxic, genotoxic, and pro-oxidant effects against AML cells while appearing to reduce DNA damage in healthy cells. The proposed mechanism involves a dual pro-oxidant/antioxidant behavior of citral that shifts cell death from necrosis toward apoptosis.
- Other names
- fraction rich in citralcitral-enriched fractionLippia alba essential oil fraction F2
02
Targets
DNA
Beyond the preview
Go deeper on citral-enriched fraction F2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on citral-enriched fraction F2.